Anixa Biosciences reports 74% immune response in Phase 1 breast cancer vaccine trial, safe at max dose. Plans for Phase 2.
The vaccine was found to be safe and well-tolerated when administered at the maximum tolerated dose. The results indicated that moving the program into Phase 2 development is feasible. A combination of Keytruda® and the vaccine was successful in generating T cell responses, with no significant additional side effects observed. This outcome boosts confidence in the plans for a Phase 2 neoadjuvant study.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments